What does receivable from collaboration agreement mean?

This represents the cash flow impact resulting from changes in accounts receivable specifically tied to research and development collaboration or licensing agreements. It reflects the timing difference between recognizing revenue from partners and the actual collection of cash payments. Monitoring this helps assess the company's ability to convert partnership-driven milestones or service fees into liquid operating capital.

Monte Rosa Therapeutics, Inc. GLUE Receivable From Collaboration Agreement

Receivable From Collaboration Agreement at other companies

BioCryst PharmaceuticalsBCRX

$3.98M+78.9%

SyscoSYY

$234M+61.4%

Kinetik HoldingsKNTK

$29.34M+52.9%

Northern TrustNTRS

$164.8M-20.0%

Walt DisneyDIS

$1.81B+41.4%

HEICOHEI

$59.87M-0.9%

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.76B+361%

Enterprise value$1.64B+381%

P/S41×+38.6×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept glue:ReceivableFromCollaborationAgreement.

The official record: Monte Rosa Therapeutics, Inc.’s 10-K, filed March 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s receivable from collaboration agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s receivable from collaboration agreement?: Monte Rosa Therapeutics, Inc. (GLUE) reported receivable from collaboration agreement of $1.75M in Q4 2025.
What does receivable from collaboration agreement mean?: This represents the cash flow impact resulting from changes in accounts receivable specifically tied to research and development collaboration or licensing agreements. It reflects the timing difference between recognizing revenue from partners and the actual collection of cash payments. Monitoring this helps assess the company's ability to convert partnership-driven milestones or service fees into liquid operating capital.